Sanofi Expands Diabetes Portfolio with $2.9 Billion Deal for Provention Bio
TZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read moreTZIELD, the first disease-modifying medication to postpone Stage 3 type 1 diabetes (T1D), will be added to Sanofi’s portfolio following
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreLonza and Context Therapeutics, a US-based clinical-stage biopharmaceutical company advancing therapeutics for solid tumors, announced that they have reached a
Read moreThis mouse specific CD19 antibody is specifically designed to detect CD19 in murine tissues with high sensitivity in FFPE applications.
Read moreApogenix, a biopharmaceutical company developing next-gen immunotherapeutics, announced on Wednesday that asunercept showed statistically meaningful benefits for hospitalized COVID-19 patients
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read moreEvusheld, a long-acting antibody (LAAB) combination from AstraZeneca, has received emergency use authorisation (EUA) by the FDA in the United
Read moreNew Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreGenentech’s investigational antibody for the treatment of early-stage Alzheimer’s disease, Gantenerumab, has been granted Breakthrough Therapy Designation by the U.S.
Read moreTakeda and JCR Pharmaceuticals announced today a geo-based exclusive collaboration and license agreement to commercialize JR-141 (INN: pabinafusp alfa), an
Read more